Business Context and Reporting Period
This Form 8-K was filed by Bristol-Myers Squibb Company on April 6, 2009. The report details strategic partnership updates and confirms financial guidance for the full year 2009.
Key Financial Metrics and Agreements
- ABILIFY Agreement Extension: Extended the U.S. development and commercialization agreement with Otsuka Pharmaceutical Co., Ltd. from November 2012 to April 2015 (expected loss of exclusivity).
- Oncology Collaboration: Established a new collaboration with Otsuka for two products: SPRYCEL (dasatinib) and IXEMPRA (ixabepilone).
- EPS Guidance: Confirmed previously disclosed full-year 2009 EPS guidance on both GAAP and non-GAAP bases.
- Future Accretion: Expects a minimum $0.30 EPS accretion in 2013 and 2014 resulting from the ABILIFY agreement extension.
- Growth Rate: Reaffirmed non-GAAP EPS compounded annual growth rate guidance from 2007 through 2010, subject to certain assumptions.
Material Changes
The primary material change is the extension of the ABILIFY partnership term, which alters the revenue timeline for this key product. Additionally, the filing introduces a new oncology collaboration scope not previously detailed in the same manner.
Guidance, Outlook, and Risks
Management confirmed its 2009 earnings outlook and long-term growth trajectory. The filing notes that the guidance is subject to certain assumptions. No specific new risks or contingencies were detailed in the text of this report beyond the standard reliance on assumptions for the growth rate guidance.
Investor Verification Checklist
- Verify the specific terms of the new oncology collaboration for SPRYCEL and IXEMPRA in the attached press release (Exhibit 99.1).
- Review the "certain assumptions" referenced regarding the 2007-2010 non-GAAP EPS growth rate guidance.
- Confirm the details of the $0.30 EPS accretion calculation for 2013 and 2014 in the supplemental information (Exhibit 99.2).
- Check for any updates to the 2009 GAAP and non-GAAP EPS figures in the full press release.